Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 24:6:100154.
doi: 10.1016/j.rcsop.2022.100154. eCollection 2022 Jun.

A content review of buprenorphine training programs for pharmacists

Scott A Davis  1 , Robyn Dryer  1 , William Zule  2 , Bayla Ostrach  3 , Delesha M Carpenter  1
Affiliations

A content review of buprenorphine training programs for pharmacists

Scott A Davis et al. Explor Res Clin Soc Pharm. .

Abstract

Objectives: To identify and describe continuing education (CE) credit-bearing training programs for pharmacists that cover buprenorphine dispensing.

Methods: Five CE databases were searched for trainings that were in English, targeted to pharmacists, addressed use of buprenorphine for opioid use disorder treatment, not state-specific, accredited by the Accreditation Council for Pharmacy Education, and available for online registration.

Results: Twelve trainings met the inclusion criteria. The most common topics covered were background and statistical information (10 trainings) and the clinical role of buprenorphine in medication assisted therapy (9 trainings). No training covered all 10 topics assessed. Seven programs included content on prescribing barriers, but of those, only two briefly addressed buprenorphine dispensing barriers, and none addressed the widespread belief that the Drug Enforcement Administration sets limits on the amount of buprenorphine that can be ordered and stocked. A majority of the programs (75%) addressed the clinical details of treatment, but only five addressed social barriers, such as stigma.

Conclusion: Future trainings should develop and increase pharmacists' awareness of content to address the gaps identified in this study so they can supplement existing trainings, especially related to DEA and wholesaler regulations and thresholds, communication, stigma, and ways of overcoming these.

Keywords: Buprenorphine; Communication; Dispensing barriers; Opioid use disorder; Training.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Shulman M., Wai J.M., Nunes E.V. Buprenorphine treatment for opioid use disorder: an overview. CNS Drugs. 2019;33(6):567–580. - PMC - PubMed
    1. Cooper H.L.F., Cloud D.H., Young A.M., Freeman P.R. When prescribing isn’t enough - pharmacy-level barriers to buprenorphine access. N Engl J Med. 2020;383(8):703–705. - PubMed
    1. Ajazi E.M., Dasgupta N., Marshall S.W., et al. Revisiting the X: BOT naltrexone clinical trial using a comprehensive survival analysis. J Addict Med. 2022 - PubMed
    1. Wakeman S.E., Larochelle M.R., Ameli O., et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2) - PubMed
    1. Hatemi P., Zorn C. Independent pharmacies in the U.S. are more on the rise than on the decline. 2020. https://www.pcmanet.org/wp-content/uploads/2020/03/FINAL_Independent-Pha... Accessed 06/09/2022.

LinkOut - more resources